Reversing Coronary Heart Disease

  • Hans Diehl


In the United States, as in many industrialized Western countries, almost every second man and woman dies from degenerative vascular disease related to atherosclerosis, a process that expresses itself most frequently as coronary artery disease, with angina and myocardial infarction as its classical manifestations. The disease is so prevalent that it has often been assumed to be a natural concomitant of the aging process.


Serum Cholesterol Serum Cholesterol Level Dietary Cholesterol Usual Medical Care Group Multiple Risk Factor Intervention Trial 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kuller L, Lilienfeld A, Fisher R. Epidemiological Study of sudden and unexpected deaths due to arteriosclerotic heart disease. Circulation 1966; 34:1056–1068.Google Scholar
  2. 2.
    Enos WF, Holmes RH, Beyer J. Coronary disease among US soldiers killed in action in Korea. JAMA 1953; 152:1090–1093.Google Scholar
  3. 3.
    Strong JP. Coronary atherosclerosis in soldiers. JAMA 1986; 256:2863–2866.Google Scholar
  4. 4.
    World Health Organization. World health statistics manual 1991. Geneva: WHO, 1992; 25,26.Google Scholar
  5. 5.
    Anitschkow N. Ueber experimentelle Cholesterin Steatose and ihre Bedeutung fixer die Entstehung einiger pathologischer Prozesse. Zbl Path 1913; 26:1–8.Google Scholar
  6. 6.
    DeLanger CD. Cholesterol metabolism in racial pathology. Geneesk Tydschr Nederl Indie 1916; 56:1–34.Google Scholar
  7. 7.
    Schettler G. Cardiovascular diseases during and after World War II: a comparison of the Federal Republic of Germany with other European countries. Prev Med 1979; 8:581–590.Google Scholar
  8. 8.
    Malmros H. The relation of nutrition to health. Acta Med Scand 1950; 246(Suppl):128–150.Google Scholar
  9. 9.
    Vartiainen I, Kanerva K. Arteriosclerosis in wartime. Ann Intern Med (Finland) 1947; 36:748–758.Google Scholar
  10. 10.
    Strom A. Mortality from circulatory diseases in Norway 1940- 1945. Lancet 1951; 260:126–129.Google Scholar
  11. 11.
    11.Castelli, WP. 1986 (personal communication).Google Scholar
  12. 12.
    Keys A, Taylor HL, Blackburn H, Brozek J, Anderson JT, Simonson E. Coronary heart disease among Minnesota business and professional men followed 15 years. Circulation 1963; 28: 381–395.Google Scholar
  13. 13.
    The Framingham Study. Kannel WB, Gordon T, eds. Washington, DC: USD HEW Public Health Service, National Institutes of Health, 1973; #74–618.Google Scholar
  14. 14.
    Kannel WB, Castelli WP, Gordon T. Cholesterol in the prediction of atherosclerotic disease; new perspective on the Framingham study. Ann Intern Med 1979; 90:85–91.Google Scholar
  15. 15.
    Seidel D, Cremer P, Nagel D. Significance of risk factors in the prediction of atherosclerosis. Atherosclerosis Rev 1991; 23:243–250.Google Scholar
  16. 16.
    Gohlke H, Gohlke-Baerwolf C, Stuerzenhofecker P, Goernandt L, Thilo A, Haakshorst W, Roskamm H. Myocardial infarction at young age: correlation of angiographic findings with risk factors and history in 619 patients. Circulation 1980; 62:111–39.Google Scholar
  17. 17.
    Gohlke H, Stuerzenhofecker P, Goernandt L, Haakshorst W, Roskamm H. Progression und Regression der koronaren Herzerkrankung im chronischen Infarktstadium bei Patienten unter 40 Jahren. Schweiz Med Wochenschr 1980 (Nov. 8); 110:1663–1665.Google Scholar
  18. 18.
    Barndt R. Serial angiographic correlations of progression and regression of atherosclerosis with risk factor levels. Arteriosclerosis 1981; 1:1–8.Google Scholar
  19. 19.
    Truett J, Cornfield J, Kannel W. A multivariate analysis of the risk of coronary heart disease in Framingham. J Chron Dis 1967; 20:511–524.Google Scholar
  20. 20.
    Coronary Risk Handbook.Estimating risk of coronary heart disease in daily practice. New York: American Heart Association, 1973.Google Scholar
  21. 21.
    Cooper T. The scientific foundation for the prevention of coronary heart disease. Am J Cardiol 1981; 47:720–724.Google Scholar
  22. 22.
    Byington R, Dyer AR, Garside D, Liu K, Moss D, Stamler J, Tsong Y. Recent trends of major coronary risk factors and CHD mortality in the US. In: Hawlik RJ, Feinleib M, eds. Proceedings of the Conference on the Decline in CHD Mortality. USD HEW Public Health Service, National Institutes of Health 1979; #79–1610.Google Scholar
  23. 23.
    Stamler J, Wentworth D, Neaton JD. Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? The MRFIT Study. JAMA 1986; 256:2823–2828.Google Scholar
  24. 24.
    Diehl H, Mannerberg D. Regression of hypertension, hyperli- pidaemia, angina and coronary heart disease. In: Trowell HC, Burkitt DP, eds. Western Diseases: Their Emergence and Prevention. London: Edward Arnold, 1981; 392–410.Google Scholar
  25. 25.
    Stamler J. Lifestyles, major risk factors, proof and public policy. Circulation 1978; 58:3–18.Google Scholar
  26. 26.
    Stamler J. The marked decline in coronary heart disease mortality rates in the United States, 1968–1981. Summary of findings and possible explanations. Cardiology 1985; 72:5–22.Google Scholar
  27. 27.
    Ignatowski A. Ueber die Wirkung des tierischen Eiweisses auf die Aorta und die parenchymatösen Organe der Kaninchen. VirchowsArch 1909; 198:248–259.Google Scholar
  28. 28.
    Taylor CB, Patton DE, Cox GE. Atherosclerosis in rhesus monkeys. Arch Pathol 1963; 76:404–412.Google Scholar
  29. 29.
    29.Wissler RW. 1990 (personal communication).Google Scholar
  30. 30.
    Armstrong ML, Warner ED, Connor WE. Regression of coronary atheromatosis in rhesus monkeys. Circ Res 1970; 27: 59–67.Google Scholar
  31. 31.
    Armstrong ML, Megan MB. Lipid depletion in atheromatous coronary arteries in rhesus monkeys after regression diets. Circ Res 1972; 30:675–680.Google Scholar
  32. 32.
    Connor, WE. Regression of Atherosclerotic Plaques. Presentation at University of California, San Francisco, Dental Alumni Convention, Jan 10, 1992.Google Scholar
  33. 33.
    McGill HC. The geographic pathology of atherosclerosis. Lab Invest 1968; 18:463–478.Google Scholar
  34. 34.
    Keys A. Coronary heart disease in seven countries. Circulation 1970; 41(Suppl. 1):1–196.Google Scholar
  35. 35.
    Keys A, Kimura N, Kusukawa A. Lessons from serum cholesterol studies in Japan, Hawaii and Los Angeles. Ann Intern Med 1958; 48:83–94.Google Scholar
  36. 36.
    Keys A. Lessons to be learned from serum cholesterol level. Ann Intern Med 1976; 61:421–430.Google Scholar
  37. 37.
    Welch CC, Proudfit WL, Sones FM, Shirey EK, Sheldon WC, Razavi M. Cinecoronary arteriography in young men. Circulation 1970; 42:647–653.Google Scholar
  38. 38.
    Page IH, Berrettoni Jr, Butkus A, Sones FM. Prediction of coronary heart disease based on clinical suspicion, age, total cholesterol and triglycerides. Circulation 1970; 42:625–640.Google Scholar
  39. 38a.
    Roberts, WG. Atherosclerotic risk factors—Are there ten or is there only one? Am J Cardiol 64:552–554.Google Scholar
  40. 39.
    Gotto A. Hearing before the Select Committee on Nutrition and Human Needs of the US Senate. Part I. CVD-DietRelated to Killer Diseases. Washington, DC: US Government Printing Office, 1977; 325–326.Google Scholar
  41. 40.
    Castelli WP. Reversing Heart Disease. Med World News 1979 (Sept. 3).Google Scholar
  42. 41.
    Consensus Conference. Lowering blood cholesterol to prevent heart disease. JAMA 1985; 253:2080–2086.Google Scholar
  43. 42.
    Pritikin N. Optimal dietary recommendations: a public health responsibility. Prev Med 1982; 11:733–739.Google Scholar
  44. 43.
    Blackburn H. Diet and atherosclerosis: epidemiologic evidence and public health implications. Prev Med 1983; 12:2–10.Google Scholar
  45. 44.
    Castelli WP, Wilson PWF, Levy D, Anderson K. Serum lipids and risk of coronary artery disease. Atherosclerosis Rev 1990; 21:7–19.Google Scholar
  46. 45.
    Ross R, Glomset JA. The pathogenesis of atherosclerosis, Parts I and II. N Engl JMed 1976; 295:369–375, 420–426.Google Scholar
  47. 46.
    Ross R. Lipoproteins, endothelial injury and atherosclerosis. CardiovascularResRep 1982; 3:1026–1033.Google Scholar
  48. 47.
    47.Majno G. The diet/atherosclerosis connection: new insights. J Cardiovasc Med 1984 (Jan.); 21–28.Google Scholar
  49. 48.
    Constantinides P, Robinson M. Ultrastructural injury of arterial endothelium. Arch Pathol 1969; 88:99–116.Google Scholar
  50. 49.
    Davies MJ, Woolf N, Katz DR. The role of endothelial denudation injury, plaque Assuring, and thrombosis in the progression of human atherosclerosis. Atherosclerosis Rev 1991; 23:105–113.Google Scholar
  51. 50.
    Astrup P. Carbon monoxide, smoking and cardiovascular disease. Circulation 1973; 48:1167,1168.Google Scholar
  52. 51.
    Wells RE. Rheology of blood microvasculature. N Engl J Med 1964; 270:832–839.Google Scholar
  53. 52.
    Swank RD, Nakamura H. Oxygen availability in brain tissues after lipid meals. Am J Physiol 1960; 198:217–220.Google Scholar
  54. 53.
    Kuo PT, Joyner CR. Angina pectoris induced by fat ingestion in patients with coronary artery disease. JAMA 1955; 158:1008–1012.Google Scholar
  55. 54.
    Williams AV. Increased cell agglutination following ingestion of fat, a factor contributing to cardiac ischemia, coronary insufficiency and anginal pain. Angiology 1957; 8:29–36.Google Scholar
  56. 55.
    Gresham GA. Is atheroma a reversible lesion? Atherosclerosis 1976; 23:379–391.Google Scholar
  57. 56.
    Stamler J. Towards cardiovascular health. Am Med 1989; 21:141–155.Google Scholar
  58. 57.
    Armstrong ML, Megan MB, Warner ED. Intimal thickening in normocholesterolemic rhesus monkeys fed low supplements of dietary cholesterol. Cire Res 1974; 34:447–454.Google Scholar
  59. 58.
    Canner PL, Berger KG, Wenger NK. Fifteen-year mortality in Coronary Drug Project patients: long-term benefit of niacin. JAm Coll Cardiol 1986; 6:1245–1255.Google Scholar
  60. 59.
    Coronary Drug Project Research Group. Factors influencing long-term prognosis after recovery from myocardial infarction. Three-year findings of the Coronary Drug Project. J Chron Dis 1974; 27:267–279.Google Scholar
  61. 60.
    Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975; 231:360–381.Google Scholar
  62. 61.
    Lipid-lowering drugs after myocardial infarction. Lancet 1975; i:501,502.Google Scholar
  63. 62.
    Committee of Principal Investigators. WHO Cooperative trial on primary prevention of ischemic heart disease using Clofibrate to lower serum cholesterol: mortality follow-up. Lancet 1980; ii:379–384.Google Scholar
  64. 63.
    The Clofibrate dilemma. Br Med J 1978; 2:1585,1586.Google Scholar
  65. 64.
    Rifkind BM, Levy RI. Testing the lipid hypothesis. Arch Surg 1978; 113:80–83.Google Scholar
  66. 65.
    Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984; 251:351–364.Google Scholar
  67. 66.
    Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984; 251:365–374.Google Scholar
  68. 67.
    Tikkanen MJ, Nikkila EA. Current treatment of elevated serum cholesterol. Circulation 1987; 76:529–533.Google Scholar
  69. 68.
    Frick MH, Elo MO, Haapa K, et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. NEnglJMed 1987; 317:1237–1245.Google Scholar
  70. 69.
    Manninen V, Elo MO, Frick MH, et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988, 260:641–651.Google Scholar
  71. 70.
    Tyroler, HA. Review of lipid-lowering clinical trials in relation to observational epidemiologic studies. Circulation 1987; 76:515–522.Google Scholar
  72. 71.
    National Research Council, Committee on Diet and Health: Diet and Health Implications for Reducing Chronic Disease Risk. Washington, DC: National Academic Press, 1989.Google Scholar
  73. 72.
    Holme I. An analysis of randomized trials evaluating the effect of cholesterol reduction on total mortality and CHD incidence. Circulation 1990; 82:1916–1924.Google Scholar
  74. 73.
    Keys A, Anderson JR, Grande F. Serum cholesterol response to changes in the diet. Metabolism 1965; 14:747–787.Google Scholar
  75. 74.
    Anderson JR, Jacobs DR, Foster N, Keys A. Scoring systems for evaluation of dietary pattern effect on serum cholesterol. Prev Med 1979; 8:525–530.Google Scholar
  76. 75.
    Hegsted DM, McGandy RB, Myers ML, Stare FJ. Quantitative effects of dietary fat on serum cholesterol in man. Am J ClinNutr 1965; 17:281–295.Google Scholar
  77. 76.
    Hegsted DM. Serum cholesterol response to dietary cholesterol: a re-evaluation. Am J Clin Nutr 1986; 44:299–305.Google Scholar
  78. 77.
    Connor WE, Stone DB, Hodges RE. The interrelated effects of dietary cholesterol and fat on human serum lipid levels. J Clin Invest 1964; 143:1691–1696.Google Scholar
  79. 78.
    Mattson FH, Erickson BA, Klingman AM. Effect of dietary cholesterol on serum cholesterol. Am J Clin Nutr 1972; 25:589–594.Google Scholar
  80. 79.
    Stamler J, Shekelle R. Dietary cholesterol and human coronary heart disease: the epidemiologic evidence. Arch Pathol Lab Med 1988; 112:1032–1040.Google Scholar
  81. 80.
    Beveridge JMR. The response of man to dietary cholesterol. JNutr 1960; 71:61–65.Google Scholar
  82. 81.
    Sacks FM. Effect of ingestion of meat on plasma cholesterol of vegetarians. JAMA 1981; 246:640–644.Google Scholar
  83. 82.
    Sacks FM. Ingestion of egg raises plasma LDL-cholesterol in free-living subjects. Lancet 1984; i:647–649.Google Scholar
  84. 83.
    Alfin-Slater R. Plasma cholesterol and triglyceride levels in men with added eggs in the diet. Nutr Rep Intl 1976; 14:249–259.Google Scholar
  85. 84.
    Flynn MA. Effect of dietary egg on human serum cholesterol and triglycerides. Am J Clin Nutr 1979; 32:1051–1057.Google Scholar
  86. 85.
    Keys A, Anderson JT, Grande F. Diet-type (fats constant) and blood lipids in man. J Nutr 1960; 70:257–269.Google Scholar
  87. 86.
    DeGroot AP, Luyken R, Pikaar NR. Cholesterol-lowering effect of rolled oats. Lancet 1963; ii:303–307.Google Scholar
  88. 87.
    Ripsin CM, Keenan JM, Jacobs DR, et al. Oat products and lipid lowering-a meta-analysis. JAMA 1992; 267:3317–3325.Google Scholar
  89. 88.
    Grundy SM. Dietary therapy for different forms of hyperlipoproteinemia. Circulation 1987; 3:523–528.Google Scholar
  90. 89.
    Ahrens EH, Hirsch J, Stoffel W, Peterson ML, Farquar JW. The effect on human serum lipid of a dietary fat, highly unsaturated, but poor in essential fatty acids. Lancet 1959; i:115–119.Google Scholar
  91. 90.
    Vega LG, Groszek E, Wolf R, Grundy SM. Influence of polyunsaturated fats on plasma lipoprotein composition and apolipoprotein. J LipidRes 1982; 23:811–818.Google Scholar
  92. 91.
    Bennion LJ, Grundy SM. Risk factors for the development of cholelithiasis in man. NEngl J Med 1978; 299:1221–1227.Google Scholar
  93. 92.
    Broitman S. Polyunsaturated fat, cholesterol and tumorigenesis. Cancer 1977; 40:2455–2459.Google Scholar
  94. 93.
    Felber JP, Vannotti A. Effects of fat infusion on glucose tolerance and insulin plasma levels. Med Exp 1964; 10:1536–1541.Google Scholar
  95. 94.
    Cullen C. Intravascular aggregation and adhesiveness of the blood elements associated with alimentary lipemia and injections of large molecular substances. Circulation 1954; 9:335–339.Google Scholar
  96. 95.
    Bansal BR, Rhoads JE, Bansal SC. Effect of diet on colon carcinogenesis and the immune systems in rats treated with 1,2-dimethylhydrazine. CancerRes 1978; 38:3293–3298.Google Scholar
  97. 96.
    Carroll K. Experimental evidence of dietary factors in hormone-dependent cancer. CancerRes 1975; 35:3374–3379.Google Scholar
  98. 97.
    Ehnholm C, Huttunen JK, Pietinen P, et al. Effect of diet on serum lipoproteins in a population with a high risk of coronary heart disease. NEngl JMed 1982; 307:850–855.Google Scholar
  99. 98.
    Barnard RJ. Effects of lifestyle modification on serum lipids. ArchInternMed 1991; 151:1389–1394.Google Scholar
  100. 99.
    Morrison LM. Reduction of mortality rate in coronary atherosclerosis by low-cholesterol, low-fat diet. Am Heart J 1951; 42:538–545.Google Scholar
  101. 100.
    Morrison LM. Diet in coronary atherosclerosis. JAMA 1960; 173:104–108.Google Scholar
  102. 101.
    Rose GA, Thompson WB, Williams RT. Corn oil in treatment of ischemic heart disease. Br Med J 1965; i:1531–1533.Google Scholar
  103. 102.
    London Research Group. Low-fat diet in myocardial infarction—a controlled trial. Lancet 1965; ii:501–504.Google Scholar
  104. 103.
    Medical Research Council, Research Committee. Controlled trial of soybean oil in myocardial infarction. Lancet 1968; ii:693–700.Google Scholar
  105. 104.
    Bierenbaum ML, Fleischman Al, Green DP. The 5-year experience of modified fat diets on younger men with CHD. Circulation 1970; 42:943–949.Google Scholar
  106. 105.
    Leren P. The Oslo Diet-Heart Study. Eleven-year report. Circulation 1970; 42:935–942.Google Scholar
  107. 106.
    Dayton S, Pearce ML, Hashimoto S, Dixon Wj, Tomiyasn M. A Controlled trial of a diet high in unsaturated fat in preventing complications of atherosclerosis. Circulation 1969; 40(Suppl. 2):1–63.Google Scholar
  108. 107.
    Turpeinen O, Karvonen MJ, Pekkarinen M. Dietary prevention of CHD—the Finnish mental hospital study. Int J Epidemiol 1979; 8:99–118.Google Scholar
  109. 108.
    Hjermann I, Byre KV, Holme I, Leren P. Effect of diet and smoking intervention on the incidence of CHD. Report from the Oslo Study Group of a randomized trial in healthy men. Lancet 1981; ii:1303–1310.Google Scholar
  110. 109.
    Hjermann I. The Oslo Study: Some trial results. Atherosclerosis Rev 1990; 21:103–108.Google Scholar
  111. 110.
    MRFIT Research Group. MRFIT-Risk factor changes and mortality results. JAMA 1982, 248:1465–1477.Google Scholar
  112. 111.
    MRFIT Research Group. Mortality rates after 10.5 years for participants in the MRFIT. JAMA 1990; 263:1795–1801.Google Scholar
  113. 112.
    McNamara DJ. Diet and hyperlipidemia—A justifiable debate. Arch Intern Med 1982; 142:112–114.Google Scholar
  114. 113.
    Ahrens EH. The diet-heart question in 1985: has it really been settled? Lancet 1985; i:1085–1087.Google Scholar
  115. 114.
    Kolata G. Heart panel’s conclusions questioned. Science 1985; 227:40–41.Google Scholar
  116. 115.
    Taylor WC, Pass TM, Shepard DS, Kamaroff AL. Cholesterol reduction and life expectancy; a model incorporating multiple risk factors. Ann Int Med 1987; 106:605–614.Google Scholar
  117. 116.
    Oliver MF. Reducing cholesterol does not reduce mortality. J Am Coll Cardiol 1988; 12:814–817.Google Scholar
  118. 117.
    Muldoon MF, Manuck SB, Matthews KA. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. Br Med J 1990; 301:309–314.Google Scholar
  119. 118.
    Oliver MF. Doubts about preventing CHD. Multiple interventions in middle-aged men may do more harm than good. Br Med J 1992; 304:393,394.Google Scholar
  120. 119.
    Ravnskov U. Cholesterol lowering trials in CHD: frequency of citation and outcome. Br Med J 1992; 305:15–19.Google Scholar
  121. 120.
    Fräser GF. Preventive Cardiology. New York: Oxford University Press, 1986.Google Scholar
  122. 121.
    Taskforce on Cholesterol Issues. The Cholesterol Facts—the summary of the evidence relating dietary facts, serum cholesterol, and CHD. Ajoint statement by the American Heart Association and the National Heart, Lung and Blood Institute. Circulation 1990; 81:1721–1733.Google Scholar
  123. 122.
    Ramsey LE, Yee WW, Jackson PR. Dietary reduction of serum cholesterol concentrations: time to think again. Br Med J 1991, 303:953–957.Google Scholar
  124. 123.
    Robinson MH. Nutrition and Physical Fitness in Public Health: The Pritikin Program. Hearing before the Committee on Labor and Human Resources, US Senate. Washington, DC: US Government Printing Office, 1986 (SHRG 99–513); 166–215.Google Scholar
  125. 124.
    Phillips RL, Kuzma JW, Beeson WL, Lötz T. Influence of selection versus lifestyle on risk of fatal cancer and cardiovascular disease among Seventh-day Adventists. Am J Epidemiol 1980; 112:296–314.Google Scholar
  126. 125.
    Phillips, RL, Garfmkel L, Kuzma JW, Beeson WL, Lötz T, Brin B. Mortality among California Seventh-day Adventists for selected cancer sites. J Natl Cancer Inst 1980; 65: 1097–1107.Google Scholar
  127. 126.
    Kahn HA, Phillips RL. Association between reported diet and all-cause mortality: Twenty-one year follow-up on 27,530 adult Seventh-day Adventists. Am J Epidemiol 1984; 119:775–787.Google Scholar
  128. 127.
    Chang-Claude J, Frentzel-Beyme R, Eilber U. Mortality pattern of German vegetarians after 11 years of follow-up. Epidemiology 1992; 3:395–401.Google Scholar
  129. 128.
    McNichael AJ. Vegetarians and longevity—imagining a wider reference population. Epidemiology 1992; 3:389–391.Google Scholar
  130. 129.
    Katz LN, Stamler J. Experimental Atherosclerosis. Springfield, IL: Charles Thomas, 1953.Google Scholar
  131. 130.
    Wissler RW, Hughes RH, Frazier LE, Getz GS, Turner DF. Aortic lesions and blood lipids in rhesus monkeys fed “table prepared” human diets. Circulation 1965; 32(Suppl. 2):220.Google Scholar
  132. 131.
    Clarkson TB, Lehner ND, Wagner WD, St.Clair RW, Bond MG, Bullock BC. A study of atherosclerosis regression in Macaca mulatta. I. Design of experiment and lesion induction. Exp Mol Pathol 1979; 30:360–385.Google Scholar
  133. 132.
    Tucker CF, Catsulis C, Strong JP, Eggen DA. Regression of early cholesterol-induced aortic lesions in rhesus monkeys. AmJPathol 1971; 65:493–514.Google Scholar
  134. 133.
    Stary HC. Progression and regression of experimental atherosclerosis in rhesus monkeys. In: Goldsmith E, Morr- Hankowsky J, eds. Medical Primatology. Basel: Karger, 1972; 356,357.Google Scholar
  135. 134.
    Vesselinovitch D, Wissler RW. Reversal of advanced atherosclerosis in rhesus monkeys. Atherosclerosis 1976,23:155–176.Google Scholar
  136. 135.
    Bond MG, Bullock BC, Clarkson TB, Lehner ND. The effect of plasma cholesterol concentrations on regression of primate atherosclerosis. Am J Pathol 1976; 82:69a.Google Scholar
  137. 136.
    Armstrong ML. Evidence of regression of atherosclerosis in primates and man. Postgrad Med J 1976; 52:456–461.Google Scholar
  138. 137.
    Wissler RW, Vesselinovitch D. Regression of atherosclerosis in experimental animals and man. Mod Concepts Cardiouasc Dis 1977; 46:27–32.Google Scholar
  139. 138.
    Wagner WD, St.Clair RW, Clarkson TB, Connor JR. A study of atherosclerosis regression in Macaca mulatta. III. Chemical changes in arteries from animals with atherosclerosis induced for 19 months and regressed for 48 months at plasma cholesterol concentrations of 300 or 200 mg%. Am J Pathol 1980; 100:633–650.Google Scholar
  140. 139.
    Clarkson TB, Bond MG, Bullock BC, Marzetta CA. A study of atherosclerosis regression in Macaca mulatta. IV. Changes in coronary arteries from animals with atherosclerosis induced for 19 months and then regressed for 24 or 48 months at plasma cholesterol concentrations of 300 or 200 mg%. Exp Mol Pathol 1981; 34:345–368.Google Scholar
  141. 140.
    Clarkson TB, Bond MG, Bullock BC, McLaughlin KJ, Sawyer JK. A study of atherosclerosis regression in Macaca mulatta. V. Changes in abdominal aorta and carotid and coronary arteries from animals with atherosclerosis induced for 38 months and then regressed for 24 or 48 months at plasma cholesterol concentrations of 300 or 200 mg%. Exp Mol Pathol 1984; 41:96–118.Google Scholar
  142. 141.
    Malinow MR. Atherosclerosis progression, regression, and resolution. Am Heart J 1984; 108:1523–1537.Google Scholar
  143. 142.
    Malinow MR, Blaton V. Regression of atherosclerotic lesions (Meeting Summary). Arteriosclerosis 1984; 4:292–295.Google Scholar
  144. 143.
    Reiber JHC, Gerbrands JJ, Booman F. Objective characterization of coronary obstructions from monoplane cineangiograms and three-dimensional reconstruction of an arterial segment from two orthogonal views. In: Schwartz MD, ed. Applications of Computers in Medicine. Circulation 1985; 71:280–288.Google Scholar
  145. 144.
    Aschoff L. Lectures in Pathology. New York: Hoeber Medical Division, Harper & Row, 1924.Google Scholar
  146. 145.
    Breitske H. Zur Entstehung der Atherosklerose. Virchows Arch 1928; 267:625–631.Google Scholar
  147. 146.
    DePalma RG, Hubay CA, Insull W, Robinson AV, Hartman PH. Progression and regression of experimental atherosclerosis. Surg Gynec Obstet 1970; 131:633–647.Google Scholar
  148. 147.
    Basta LL. Regression of atherosclerotic stenosing lesions of the renal arteries and spontaneous cures of systemic hypertension through control of hyperlipidemia. Am J Med 1976; 61:420–423.Google Scholar
  149. 148.
    Crawford DW, Sanmarco ME, Blankenborn DH. Spatial reconstruction of human femoral atheromas showing regression. Am J Med 1979; 66:784–789.Google Scholar
  150. 149.
    Roth D, Kostuk WJ. Non-invasive and invasive demonstration of spontaneous regression of coronary artery disease. Circulation 1980; 62:888–896.Google Scholar
  151. 150.
    Buchwald H, Moore RB, Rucker RD, Amplatz K, Castenada WR, Franeoz RA, Pasternak AC, Vareo RL. POSCH Arteriography Review Panel. Clinical angiographic regression of atherosclerosis after partial ileal bypass.Atherosclerosis 1983; 16:117–124.Google Scholar
  152. 151.
    Hubbard JD, Inkiles S, Barnard RJ. Nathan Pritikin’s Heart. NEnglJMed 1985; 313:52,53.Google Scholar
  153. 152.
    Brown BG, Bolson EL, Dodge HT. Arteriographie assessment of coronary atherosclerosis: review of current methods, their limitations, and clinical applications. Arteriosclerosis 1982; 2:2–15.Google Scholar
  154. 153.
    Bruschke AVG, Wijers TS, Kolsters W, Landmann J. The anatomic evolution of coronary artery disease demonstrated by coronary arteriography in 256 nonoperated patients. Circulation 1981; 63:527–534.Google Scholar
  155. 154.
    Ost RC, Stenson S. Regression of peripheral atherosclerosis during therapy with high doses of nicotinic acid. Scand J Clin Lab Invest 1967; 99(Suppl.):241–245.Google Scholar
  156. 155.
    Buchwald H, Moore RB, Varco RL. Surgical treatment of hyperlipidemia. Circulation 1974; 49(Suppl. 1):1–12.Google Scholar
  157. 156.
    Barndt R, Blankenhorn DH, Crawford DW, Brooks SH. Regression and progression of early femoral atherosclerosis in treated hyperlipoproteinemic patients. Ann Int Med 1977; 86:139–146.Google Scholar
  158. 157.
    Kuo PT, Hayase K, Kostis JB, Moreyra AE. Use of combined diet and colestipol in long-term (7–7-V2 years) treatment of patients with hyperlipoproteinemia. Circulation 1979; 59:199–207.Google Scholar
  159. 158.
    Rafflenbeul W, Smith LR, Rogers WJ, Mantle JA, Rackley CE, Russell RO. Quantitative coronary arteriography. Coronary anatomy of patients with unstable angina pectoris reexamined one year after optimal medical therapy. Am J Cardiol 1979; 49:699–706.Google Scholar
  160. 159.
    Erikson U, Helmius G, Hemmingsson A, Ruhn G, Olsson AG. Measurement of atherosclerosis by arteriography and micro- densitometry: model and clinical investigation. In: Schettler FG, Gotto AM, Middelhoff F, Habenicht AJ, Jurutka KR, eds. Atherosclerosis. Proceedings of the Sixth International Symposium on Atherosclerosis. Berlin: Springer Verlag, 1983.Google Scholar
  161. 160.
    Duffield RG, Lewis B, Miller NE, Jamieson CW, Brunt JN, Colchester AC. Treatment of hyperlipidaemia retards progression of symptomatic femoral atherosclerosis. A randomised controlled trial. Lancet 1983; ii:639–642.Google Scholar
  162. 161.
    Nikkila EA, Viikinkoski P, Valle M, Frick MH. Prevention of progression of coronary atherosclerosis by treatment of hyper- lipidaemia: a 7-year prospective angiographic study. Br Med J 1984; 289:220–223.Google Scholar
  163. 162.
    Brensike JF, Levy RI, Kelsey SF, et al. Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: Results of the NHLBI Type II Coronary Intervention Study. Circulation 1984; 69:313–324.Google Scholar
  164. 163.
    Blankenhorn D, Nessim S, Johnson R, Sanmarco M, Azen A, Cashin-Hemphill L. Beneficial effects of combined colestipol- niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987; 257:3233–3240.Google Scholar
  165. 164.
    Cashin-Hemphill L, Sanmarco ME, Blankenhorn DH. Augmented beneficial effects of colestipol niacin therapy at four years in the CLAS trial [Abstract]. Circulation 1989; 80:11–381.Google Scholar
  166. 165.
    Dintenfass L. Effect of a low-fat, low-protein diet on blood viscosity factors in patients with cardiovascular disorders. Med J Australia 1982; 1:543,544.Google Scholar
  167. 166.
    Arntzenius AC, Kromhout D, Barth JD, et al. Diet, lipoproteins and the progression of coronary atherosclerosis. NEngl JMed 1985; 312:805–811.Google Scholar
  168. 167.
    Ornish D, Brown SE, Scherwitz LW, et al. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet 1990; ii:129–133.Google Scholar
  169. 168.
    Barnard ND, Scherwitz LW, Ornish D. Adherence and acceptability of a low-fat, vegetarian diet among patients with cardiac disease. J Cardiopulmonary Rehab 1992; 12:423–431.Google Scholar
  170. 169.
    Diehl HA. Does it really cost more to eat healthy? Lifeline Health Lett 1992; 7(6):10,11.Google Scholar
  171. 170.
    Ornish D. Can lifestyle changes reverse coronary atherosclerosis? Hosp Pract 1991 (May 15); 123–132.Google Scholar
  172. 171.
    Watts GF, Lewis B, Brunt JNH, et al. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St. Thomas’ Atherosclerosis Regression Study (STARS). Lancet 1992; ii:563–569.Google Scholar
  173. 172.
    Roberts WC. Lipid-lowering therapy after an atherosclerotic event. Am J Cardiol 1989; 64:693–695.Google Scholar
  174. 173.
    Blankenhorn, DH. Atherosclerosis regression in humans. AtherosclerosisRev 1990; 21:151–157.Google Scholar

Copyright information

© Humana Press, Totowa, NJ 1994

Authors and Affiliations

  • Hans Diehl

There are no affiliations available

Personalised recommendations